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A DNA vaccine based on the VP2 gene of infectious pancreatic necrosis virus (IPNV) was incorporated into
feed to evaluate the effectiveness of this oral delivery method in rainbow trout. Lyophilized alginate
eplasmid complexes were added to feed dissolved in water and the mixture was then lyophilized again.
We compared rainbow trout that were fed for 3 consecutive days with vaccine pellets with ﬁsh that
received the empty plasmid or a commercial pellet. VP2 gene expression could be detected in tissues of
different organs in the rainbow trout that received the pcDNA-VP2 coated feed (kidney, spleen, gut and
gill) throughout the 15 day time-course of the experiments. This pcDNA-VP2 vaccine clearly induced an
innate and speciﬁc immune-response, signiﬁcantly up-regulating IFN-1, IFN-g, Mx-1, IL8, IL12, IgM and
IgT expression. Strong protection, with relative survival rates of 78%e85.9% were recorded in the
vaccinated trout, which produced detectable levels of anti-IPNV neutralizing antibodies during 90 days at
least. Indeed, IPNV replication was signiﬁcantly down-regulated in the vaccinated ﬁsh 45 days pi.
 2014 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-SA license.1. Introduction
The control of infectious diseases is essential to maintain the
levels of productivity in the aquaculture industry. The economic
impact of infectious diseases, particularly those of viral aetiology, is
a constant worldwide threat in the salmonid ﬁsh industry, stimu-
lating research to ﬁnd efﬁcient methods to minimize such losses.
Vaccination is the most effective approach to combat disease in
aquaculture, a strategy that is ideal to prevent and avoid the
dispersion of infective viruses in ﬁsh, particularly in farms where
ﬁsh are raised under intensive culture conditions. Although
different types of viral vaccines have been described for ﬁsh,
including inactivated, attenuated, synthetic peptides or subunit
vaccines [1e3], protection is not always complete. Hence, studies
are necessary to produce improved vaccines capable of inducing
longer lasting immunity and less stressful methods of administra-
tion [4]. Genetic vaccines were ﬁrst developed for mammals in the
1990s and several designs to protect against rhabdoviruses have
been tested in salmonid ﬁsh species [5e12]. More recently, other
DNA vaccines have been described to combat the infectiousþ34 915360432.
).
Ltd. Open access under CC BY-NC-SA pancreatic necrosis virus (IPNV), another viral pathogen of
salmonid ﬁsh [13e15].
Infectious pancreatic necrosis virus (IPNV) is the type species of
the Aquabirnavirus genus, from the Birnaviridae family [16]. Virions
are non-enveloped and they contain two segments (A, B) of double-
stranded RNA. Segment A is the larger of the two (about 3.1 kbp)
and it encodes VP2 and VP3, the two major structural proteins of
the virus [17,18]. The VP2 protein is the type-speciﬁc antigen that
can induce the production of neutralizing antibodies that are
capable of protecting susceptible ﬁsh from viral infection [19e21].
IPNV is one of the main causes of mortality worldwide for juvenile
salmonid ﬁsh, being especially destructive in salmonid eggs and
ﬁngerlings [22]. Fish surviving IPN epizootics develop a persistent
viral infection or carrier state, capable of continually transmitting
the virus to other susceptible populations of ﬁsh, including their
own offspring [23e26] (for reviews see Refs. [22,27,28]).
Genetic vaccination for IPNV has only recently been undertaken
experimentally, and the initial steps in its development have
focused on traditional injection methods [13]. Intramuscular in-
jection of DNA vaccines has been successfully used against viruses
such as infectious haematopoietic necrosis virus (IHNV) or viral
haemorrhagic septicaemia virus (VHSV). Intraperitoneal injection
has also been routinely used for other vaccines, such as recombi-
nant vaccines andmultivalent products, and automated systems forlicense.
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easier to administer and they represent an important alternative to
immunize ﬁsh against viruses. Nevertheless, there are still few re-
ports of successful vaccine delivery methods other than injection,
with delivery in feed having been mostly licensed to prevent bac-
terial but not viral diseases [4].
We previously described a DNA vaccine derived from the VP2
gene of IPNV inserted into an expression plasmid and encapsulated
into alginate microspheres. The oral delivery of the plasmid
(diluted in PBS) was performed manually in order to ensure the
uniform vaccination of the ﬁsh under study. Strong protection was
achieved in this way, with around 83% relative survival when
challenged 15 and 30 days after vaccine delivery. Indeed, strong
expression of IFN and the IFN-induced antiviral Mx protein was
recorded 7 and 15 days post-vaccination (pv) [14,29]. However,
novel approaches to improve the efﬁcacy of DNA vaccine oral de-
livery would not only provide interesting data regarding the future
mass delivery of these vaccines but also, keys to understand the
cellular and mucosal immunity reactions. Oral delivery of DNA
vaccines is a process that has been poorly explored, especially
against IPNV. Thus, having generated a vaccine that successfully
induces appropriate immune protective responses, the next step
should be to check if this vaccine can be delivered in feed without
losing its beneﬁcial effects due to the severe conditions experi-
enced during gastrointestinal transit.
The goal of the present work was to determine the effectiveness
against IPNV of the pcDNA-VP2-encapsulated in alginate and
incorporated into ﬁsh feed, and the immune responses it induces in
rainbow trout. Given that this method appears to produce similar
results to those described previously, its potential should be further
assessed for industrial application.
2. Materials and methods
2.1. Ethics statement
The experiments described comply with the Guidelines of the
European Union Council http://ec.europa.eu/environment/
chemicals/lab_animals/legislation_en.htm (Directive 2010/63/EU)
for the protection of animals used for scientiﬁc purposes and were
previously approved by the CSIC Ethics committee.
2.2. Cells and virus
The BF-2 cell line from bluegill fry (Lepomis macrochirus, ATCC-
CCL 91) was used to isolate and propagate the viruses. The IPNV Sp
strain from the ATCC was used in this study (ATCC VR 1318), and all
the cells and viruses were cultured as described previously [30].
Brieﬂy, cells were grown at 25 C in Leibovitz’s medium (L15, Gibco,
Spain) supplemented with 100 IU mL1 penicillin G, 100 mg mL1
streptomycin, 2 mM L-glutamine and 10% foetal bovine serum (FBS:
Gibco, Spain), or with 2% FBS in the maintenance medium (MM).
The virus was cultured in L-15 medium and propagated at 20 C.
The virus was titrated in 96-well culture plates (Falcon, Bectone
Dickinson) infected with 10-fold serial dilutions and the plates
were observed daily for the development of a cytopathic effect
(CPE). The infective titres were determined as the 50% infective
dose in tissue culture (TCID50 mL1): based on Reed &Muench [31].
2.3. Fish
Rainbow trout (3.5e4 cm and 1.5 g mean size and weight) were
purchased from a local spring water farm with no history of viral
disease. The ﬁsh were kept at the “Centro de Investigaciones Bio-
lógicas” (CSIC, Madrid, Spain) under a 12/12 h light/dark regime at15 C in 350 L closed re-circulating water tanks (Living Stream,
Frigid Units Inc, Ohio). The ﬁsh were fed daily with a diet of com-
mercial pellets and they were maintained as described elsewhere
[32]. To assess their health, pools of ﬁve ﬁsh were examined for
viruses by standard protocols [33,34], none of the ﬁsh lots exam-
ined giving positive results. The trout were anaesthetized with
buffered tricaine methanesulphonate (MS-222, Sigma) prior to
handling and the experiments described comply with the European
Union Guidelines (86/609/EU) for the use of laboratory animals.
2.4. Oral vaccination
2.4.1. Vaccine and preparation of ﬁsh feed
The pcDNA-VP2 plasmid in Escherichia coli (TOP10) was pre-
pared as described previously [14]. Cultures were grown in 10 L of
LB broth and the cells were then recovered by centrifugation and
frozen at 20 C. The plasmid was puriﬁed from the cells using the
QIAGEN plasmid Maxi Kit (Qiagen) according to the manufacturer’s
instructions. The pcDNA-VP2 and pcDNA plasmids were coated
with sodium alginate and these microspheres were prepared as
described previously [29]. The feed (T-2.0 Nutra from Trow España
S.A, Burgos, Spain) was that recommended for ﬁsh that are
approximately 3.5 cm long and that weigh 1.5 g, and it was the
same as that used at the farm that provided the rainbow trout. This
feed contains 54% protein from ﬁsh-meal, 18% oil, 1% cellulose,11.5%
ash, 3% calcium, 1.2% sodium and 1.7% phosphorus, as well as
several other oligo-elements and anti-oxidants. The particle size
ranged from 1.0 to 1.7 mm.
In our previous studies with vaccineealginate complexes, the
ﬁsh received daily drops containing 10 mg vaccine. In the present
work, the size and weight of the vaccinated trout were similar
(3.5 cm, 1.5 g) and since the ﬁsh are thought to ingest around 5% of
their body weight daily, each ﬁsh should receive 0.075 g of feed/
day. Thus, the experimental vaccine was prepared in lots of feed for
120 fry trout by placing commercial dry pellets (27 g) into 50 ml
Falcon tubes and along with 3.6 mg of pcDNA-VP2-alginate mi-
crospheres previously diluted in 15ml of distilled water. The pellets
and microspheres were then mixed gently for a few minutes at
room temperature, and the middle-moist feed obtained was
lyophilized for 24e48 h and conserved at 4 C until it was used. In
this way, a vaccine concentration of 10 mg per ﬁsh and day was
achieved.
2.4.2. Fish vaccination
Groups of 25 trout were placed in separate 40 L aquaria main-
tained at a constant temperature of 15 C for treatment. The ﬁrst
group of ﬁsh was vaccinated by providing with vaccine impreg-
nated food pellets at 5% of body weight for three consecutive days
(10 mg pcDNA-VP2/ﬁsh/day). The second group of rainbow trout
was fed with pellets mixed with the empty pcDNA plasmid, serving
as the plasmid control, and the third group of ﬁsh received the
commercial pellets and was considered as the untreated mock
vaccinated ﬁsh control. An additional group of ﬁsh were vaccinated
individually with a pcDNA-VP2 alginate microspheres solution in
water, and used as a positive control in the light of the results ob-
tained with this method elsewhere [29].
2.4.3. Tissue distribution and time-course of pcDNA-VP2 expression
At 1, 3, 5 and 15 days pv (after the last feed), 3 trout from each
group were sacriﬁced with an overdose of MS-222, and the kidney,
spleen, liver, gut and gill tissue was removed aseptically. Total RNA
was isolated using the TRIzol reagent (Invitrogen, Spain), according
to the manufacturer’s instructions, and treated with DNase I to
remove any trace genomic DNA that might interfere with the PCR
reactions. Equal amounts of RNA were primed with oligo(dT) and
Fig. 1. Relative quantiﬁcation of VP2 gene expression assessed by real-time PCR. Total
mRNA was obtained from different tissues (head kidney, spleen, gut, and gill) at 1, 3, 5
and 15 days post-vaccination with pcDNA-VP2. The vaccine was incorporated into
commercial pellets and the ﬁsh were fed the DNA vaccine diet on three consecutive
days. The ﬁrst day without feeding vaccine pellets was considered day 1 post-
vaccination. The data are shown as the mean gene expression relative to the expres-
sion of the endogenous control EF-1a (2DCt method). The error bars represent the St.
dev. of the mean (n ¼ 3).
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real-time PCR as described previously [14,34,35].
2.4.4. Gene expression
At days 1, 2, 3, 5 and 7 pv, trout were sacriﬁced (n ¼ 3) and the
head kidneys were processed for RNA extraction. We analysed the
expression of ﬁve genes by RT-qPCR, three belonging to interferon-
related pathways (IFN-1 [36], IFNg [37] and Mx-1 [38e40] and two
interleukins IL8 [41] and IL12 [42]). On days 15 and 30 pv, the
kidney of trout (n ¼ 3) from each group was also processed to
evaluate the expression of genes related to adaptive immune re-
sponses, such as IgM [43] and IgT [44]. All the primers used had
been reported and optimized in previous studies [34,35]. The
transcription of CD4 and CD8 Th cell markers was also assessed
using the primers CCTGCTCATCCACAGCCTAT (F) and
CTTCTCCTGGCTGTCTGACC (R) for CD4 and AGTCGTGCAAAGTGG-
GAAAG (F) and GGTTGCAATGGCATACAGTC (R) for CD8. The corre-
sponding accession numbers are AY973030.1 and NM_001124263,
respectively. All qPCR reactions were performed in triplicate and for
each mRNA, and gene expression was normalized to that of the
endogenous control (elongation factor 1-a; EF1-a) and expressed as
2DCt, where DCt was determined by subtracting the average EF1-a
Ct value from the average target Ct. The change in expression
relative to the empty plasmid pcDNAwas also determined for some
of the samples by applying the formula 2DDCt [45] where
DDCt¼ DCt of samples of target geneDCt of the calibrator (pcDNA
control).
2.5. Titration of neutralizing antibodies
A neutralization test (NT) was used to evaluate the speciﬁc
immune response against IPNV in the vaccinated trout. Fish blood
was collected by caudal puncture at 15, 30, 60, and 90 days pv, and
the IPNV neutralizing antibody titre was analysed in the serum of
individual ﬁsh. This assay involved incubating a two-fold dilution of
the serum with a known amount of reference IPNV, and the mix-
tures were then assayed in triplicate on BF-2 cells. Similarly, IHNV
was also tested to assess the speciﬁcity of the reaction. After
incubating for 3 days, the cell cultures were ﬁxed and stainedwith a
crystal violet solution (2% in ethanol). The titre of a serum was
determined as the reciprocal of the serum dilution that reduced
viral infectivity by approximately 50% when compared to the virus
control (TCID50 mL1). Titres >40 were considered positive.
2.6. IPNV challenge
To examine the efﬁcacy of the DNA vaccine, the vaccinated and
control groups of ﬁshwere challengedwith IPNV andmonitored for
cumulative mortality. Rainbow trout were divided into three
groups (25 ﬁsh each) and were vaccinated by feeding with pellets
containing the encapsulated pcDNA-VP2 plasmid on 3 consecutive
days (10 mg DNA/ﬁsh/day: group 1). A second group 2 received
similar amounts of pellets impregnated with the encapsulated
empty pcDNA plasmid and the third group of ﬁsh was fed with
commercial pellets. An additional group of ﬁsh were vaccinated
individually with a pcDNA.VP2 alginate microspheres solution in
water, and used as a positive control in the light of the results ob-
tained with this method elsewhere. Water quality was maintained
at optimum levels and all tanks were kept under equivalent con-
ditions. On day 15 or 30 pv, each group of ﬁsh were challenged with
IPNV by immersion (1  106 TCID50 mL1), as described previously
[29]. Fish mortality in each group was subsequently recorded and
any dead ﬁsh were removed daily over the next 30 days.
Vaccine efﬁcacy was determined by comparing the average
cumulative percentage of mortality (cpm) and the relativepercentage of survival (RPS: [1  (% mortality in vaccinated ﬁsh/%
mortality in control ﬁsh)  100]). Two replicas of the trial were
carried out.
2.7. Expression of the IPNV-VP4 gene in ﬁsh after vaccination and
IPNV challenge. Isolation of virus from survivors
The expression of the IPNV-VP4 gene was used as a measure of
the replication of IPNV in the control ﬁsh, and in the vaccinated and
infected ﬁsh. Three trout from each group were sacriﬁced with an
overdose of MS-222 on day 45 post-infection (pi) and their kidney
tissue was removed aseptically. Total RNA was isolated and cDNAs
were synthesized to analyse IPNV-VP4 gene expression by real-
time PCR (see above). The VP4 gene serves as a marker of IPNV,
making it possible to distinguish the VP2 vaccine expression from
the IPN viral expression. The relative level of infection in the
vaccinated and infected ﬁsh was then estimated by RT-qPCR
analysis.
The virus was isolated by processing head kidney samples from
the same ﬁsh assayed by RT-qPCR, and BF-2 cells were inoculated
with aliquots of the homogenates as described previously [32].
2.8. Statistical analysis
Prior to performing statistical analyses, the normal distribution
of the data was checked and conﬁrmed using the ShapiroeWilk
test. The data are presented as the mean  standard deviation (St.
dev.) of the results from three trout. An analysis of variance
(factorial ANOVAs) was run to determine whether the differentially
expressed gene differed between the replicates for each individual
gene, followed by Tukey’s multiple comparison test to assess the
differences between the vaccinated and control group. The Student
t-test was also used to compare some paired samples. All statistics
were analysed with the IBM SPSS Statistics package, an integrated
family of products that addresses the entire analytical process, from
planning and data collection to analysis, reporting and deployment
Fig. 2. The change in expression of immune innate-related genes assayed by RT-qPCR
in the rainbow trout kidney at 1, 2, 3, 5 and 7 days post-vaccination with pcDNA-VP2
plasmid incorporated into the diet. The vaccine was administered on three consecutive
days and the ﬁrst day without feeding vaccine pellets was considered day 1 post-
vaccination. The head kidney tissue from 3 ﬁsh was collected and the RNA extracted
for RT-qPCR analysis, which was performed in triplicate. The endogenous EF-1a gene
was used to normalize the results and the data are presented as the mean fold increase
relative to ﬁsh fed with the pcDNA empty plasmid pellets (standard error: 2DDCt
method). Asterisks indicate signiﬁcant differences (P  0.05) relative to the data from
day 1.
Fig. 3. The change in expression of IgM, IgT, CD4 and CD8, adaptive-related immune
genes, assayed by RT-qPCR in rainbow trout kidney 15 and 30 days after dietary
pcDNA-VP2 vaccination. The vaccine was administered on 3 consecutive days and the
ﬁrst day without feeding vaccine pellets was considered day 1 post-vaccination. A
second group of ﬁsh received the food pellets impregnated with the empty pcDNA
plasmid. Total mRNA was obtained from the head kidney and the fold increase in
transcripts compared to the empty plasmid controls was assessed. The error bars
represent the St. dev. of the mean (n ¼ 3) and the asterisks indicate statistically sig-
niﬁcant differences relative to the control at 15 days pv (P  0.05).
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considered signiﬁcant.
3. Results
3.1. Tissue distribution of the VP2 gene
To assess whether the DNA vaccine delivery approach tested
may be suitable for immunization against IPNV, the tissue distri-
bution of the VP2 gene was ﬁrst studied. The presence of mRNA-
VP2 was quantiﬁed in several organs over time and in the kidney
of the vaccinated ﬁsh, and VP2 gene expression increased strongly
from 3 days to at least 15 days pv.When compared to the ﬁsh tested
on day 1, relative increases in expression of around 4.7 fold and 12.5
fold were detected at 3 and 15 days pv, respectively (Fig. 1). The
spleenwas the organwhere the weakest relative expression of VP2
was recorded at any of the time points selected. The strongest
expression of VP2 was recorded in the gut with an increase at 3
days and with a peak of expression on the 5th day, when the
relative expression was around 52-fold that on day 1. However VP2
expression in the gut decreased dramatically to basal levels on the
15th day. This VP2 transcript was also detected in the gill, although
again at lower levels.
3.2. Transcriptional changes of immune-related genes in the kidney
of rainbow trout 7 days post-vaccination
We previously used a speciﬁc microarray to analyse the genes
expressed by rainbow trout 7 days pv with the pcDNA-VP2 [34].
Some of the genes found to be differentially expressed in the
vaccinated ﬁsh, and/or induced during IPNV infection of trout, were
also studied here. These expression proﬁles were evaluated to
demonstrate that oral delivery of the plasmid and VP2 expression
induced innate and adaptive responses.
Administration of pcDNA-VP2 in the feed induced a strong in-
crease in the expression of the genes selected to reﬂect an innate-
immune response to the virus. The increase in expression of the
marker genes induced in vaccinated ﬁsh is shown relative to the
ﬁsh that received pellets containing the empty plasmid (pcDNA:
Fig. 2). The increase in expression induced by the pcDNA-VP2
vaccine was strongest for IFN-1 and IL12, with values ranging
from 57 to 82-fold, while the expression of the Mx-1 and IL-8 was
also up-regulated on day 3 pv (25- and 47-fold, respectively). The
expression of all the genes tested was signiﬁcantly up-regulated for
several days, with the highest increases observed on the second to
the third day pv. The signiﬁcant up-regulation of IL-12 gene
expression persisted throughout the experiment and it was
approximately 13-fold at 7 days pv. By contrast, the mRNA
expression of all the other genes decreased to near basal levels at 7
days pv.
3.3. Transcriptional changes in several adaptive immune-related
genes in the kidney of rainbow trout at 15 and 30 days post-
vaccination
Of themany genes involved in the speciﬁc immune-responsewe
choose to study: i) the IgM gene that is related to cellular immune
responses; ii) IgT, recently associated with mucosal immunology;
and iii) the expression of the CD4 and CD8 genes, T-cell markers,
considered to play an important role in eliminating virus-infected
cells. The changes in gene expression in vaccinated ﬁsh relative to
the pcDNA group of ﬁsh were assessed (Fig. 3) and the strong IgM
and IgT expression detected in the kidneys 15 days pv increased
signiﬁcantly at 30 days pv (around 17- and 11-fold, respectively). Bycontrast, appreciable levels of CD4 and CD8 genes were recorded
but no signiﬁcant changes were observed at the times assayed.
3.4. Neutralizing antibodies
The anti-IPNV neutralizing antibodies were examined in serum
samples from ﬁsh at 15, 30, 60 and 90 days pv (Table 1). Anti-IPNV
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fed with pcDNA-VP2 and tested at 15 and 30 days pv, whereas all
the ﬁsh tested at 60 and 80 days had anti-IPNV.VP2 antibodies.
Neutralizing titres were higher in these late groups, from 160 to
640. No antibodies against IPNV were detected in the sera from the
control ﬁsh (saline solution administered) and ﬁsh that received
the empty plasmid pcDNA. In these studies a titre 40 was deﬁned
as positive and low titres of anti-IPNV neutralizing antibody were
only observed in 3 of the 40 total vaccinated ﬁsh.
The speciﬁcity of the induced antibody was demonstrated by
the failure to neutralize IHNV. A progressive increase in the anti-
IPNV neutralizing antibodies was recorded, demonstrating the
antigenic potential of the VP2 gene.
3.5. Cumulative mortality and relative percent survival (RPS) after
IPNV challenge to vaccinated ﬁsh
When rainbow trout were analysed 15 or 30 days pv and chal-
lenged with IPNV (Fig. 4), a cumulative mortality of 83% was
observed in the challenged control ﬁsh (A: IPNV control), as well as
in the ﬁsh fed pellets containing the empty pcDNA plasmid (B).
When the kinetics of mortality were analysed in this later group, it
was slightly retarded with respect to the virus control group until
the 20th day post-challenge when the mortality rates were similar.
By contrast, the ﬁsh vaccinated via the feed were strongly pro-
tected, with a relative percent survival (RPS) of around 86%. Simi-
larly and as expected, there was strong protection of ﬁsh that
received the vaccine individually as a microspheres emulsion
delivered by pipette (RPS ¼ 73e76%), in which the onset of mor-
tality was also delayed when they were challenged at 30 day pv.
However, in this particular group the cumulative mortality proﬁle
was the highest of all the groups vaccinated in these experiments.
The ﬁsh vaccinated individually or through the feed, and that were
challenged on the 15th day pv, exhibited parallel mortality curves
from 15 to 25 days post challenge. Likewise, similar proportions of
these ﬁsh died, and they also resisted the challenge better than the
corresponding groups challenged at 30 days pv. Nevertheless, at theTable 1
Neutralizing antibody titres in sera samples from ﬁsh immunized with the vaccine or th
Samples Days post-vaccination
15 30 60 90
pcDNA-VP2a 80 320 320 160
160 80 160 640
80 40 320 160
160 80 640 640
80 80 640 320
160 320 320 160
160 40 160 640
80 80 320 320
40 160 160 320
80 160 320 320
<20 <20 <20 <20
pcDNA-VP2b <20 <20 <20 <20
<20 <20 <20 <20
20 40 20 40
0 20 20 10
pcDNAa 10 5 20 20
10 20 10 20
5 10 10 40
Saline solutiona,b 0 0 0 0
pcDNA-VP2: Sera from ﬁsh fed with plasmid that encodes the IPNV VP2 gene; pcDNA: S
Different ﬁsh were examined from 15 to 90 days post-vaccination. The antibody titre is
dardized virus.
The histograms show mean values of neutralization titres against IPNV. Bars represent s
a Sera tested against IPNV.
b Sera tested against IHNV.end of the experiment the strongest protection was induced in the
ﬁsh administered the vaccine with the feed and that were chal-
lenged at 15 or 30 days pv (85.9% and 78.2% RPS, respectively),
reﬂecting the efﬁciency of vaccination by this route of
administration.
3.6. Expression of the VP4 gene from IPNV at 45 days post-challenge
and the isolation of the virus from survivors
Viral gene transcription that involved the VP4 gene was ana-
lysed by real-time PCR using RNA from the head kidney as the
template to evaluate viral load. The expression of the gene encod-
ing the IPNV-VP4 protein was determined by RT-qPCR in the ﬁsh
that survived 45 days post-challenge, those infected control ﬁsh
group (n ¼ 3), as well as in the vaccinated and challenged ﬁsh
(n ¼ 3). The VP4 gene was examined so as to distinguish between
vaccinated and infected trout (Fig. 5), and its expression in the virus
control group was 7-fold greater than in the vaccinated and
infected ﬁsh in which there was a signiﬁcant reduction in expres-
sion. These results suggest that IPNV replication was signiﬁcantly
down-regulated or that very low levels of the virus were found in
the vaccinated ﬁsh 45 days pi.
4. Discussion
The present study set out to determine if addition of an IPNV-
DNA vaccine to food pellets could serve as an efﬁcient method of
vaccine delivery, inducing an immune response and protecting
rainbow trout against IPNV infection. Accordingly, we demon-
strated that this vaccine was taken up by the ﬁsh and that the
plasmid passed across the gut barrier, allowing the transcript to be
efﬁciently expressed. The time-course experiments over 15 days
conﬁrmed the expression of the antigenic gene in all the organs
examined. Among these, vaccine expression was strongest in the
kidney for at least the ﬁrst 15 days pv, while the expression in the
gut peaked at 5 days pv but decreased to basal levels at 15 days pv.
This proﬁle could be explained by the abundant presence of thee pcDNA plasmid in the feed.
era from ﬁsh fed with empty plasmid.
the reciprocal of the highest dilution of the antiserum protecting against the stan-
tandard deviation.
Fig. 4. Cumulative mortality of rainbow trout (1.5 g mean weight) challenged by immersion with 5  105 TCID50 mL1 of IPNV. The ﬁsh (n ¼ 20 in duplicate tanks) were (A) mock-
vaccinated with commercial food pellets and infected with IPNV, (B) mock-vaccinated with the empty pcDNA plasmid and infected with IPNV; (C, D) fed pellets incorporating the
pcDNA-VP2 vaccine on 3 consecutive days and infected with IPNV; (E, F) pcDNA-VP2 vaccine individually administered by pipette tip. The ﬁsh were challenged on post-vaccination
day 30 (C and E) and 15 (D and F), and monitored for up to 30 days.
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across the intestinal barrier into the bloodstream, as suggested for
other vaccines [46].
The expression of some representative genes was assayed to
determine whether the vaccine was eliciting an immune response.Fig. 5. Relative expression of the IPNV-VP4 gene in the IPNV infected ﬁsh, and in the
vaccinated and challenged ﬁsh group 45 days post-challenge. The ﬁsh were vaccinated
with pcDNA-VP2 through the diet on 3 consecutive days and they were then chal-
lenged with the virus (5  105 TCID50 mL1) after 30 days. A second group was mock-
vaccinated and infected with IPNV (virus control group). Transcription of the VP4 gene
was recorded in the kidneys of both vaccinated and virus control ﬁsh at 45 days post-
challenge, and the data are represented relative to EF1-a expression (2DCt method),
(mean þ S.E., n ¼ 3). Values with asterisks are signiﬁcantly different (P  0.05).The transcriptional proﬁle of genes involved in the immune response
in the trout head kidney was determined previously by microarray
hybridization after oral administration of the vaccine (plasmide
alginate complexes in water, administered individually through a
pipette tip) [34]. From the large number of the genes up-regulated,
fourteen of those related to immune responses were selected for
quantitative RT-qPCR validation. In the presentwork, several IFN and
interleukin-related genes, aswell as the IgMand IgTgenes, from that
studywere selected to analyse the time-course of their expression in
the head kidney. These geneswere considered to be suitablemarkers
to assess the immunization procedure related to both the innate and
speciﬁc responses. Other immune markers, such as those of the CD4
and CD8 T-cell lineage, have only recently been characterized in
salmonids and their expression was determined here.
Among the non-speciﬁc immune events, it is well established
that ﬁsh can secrete type I interferon in response to viral infection
and it is one of the gene markers used to studying the early pro-
tection induced by a vaccine. Our results clearly show that the
pcDNA-VP2 vaccine up-regulates IFN-1 expression, with early in-
creases of around 57-fold with respect to the empty plasmid. A
comparison with previous results with the alginate coated vaccine
[29] suggests that the expression of the innate-immune-related
genes was clearly higher in the ﬁsh fed with pcDNA-VP2 vaccine
pellets. As expected, IFN-1 was expressed most strongly 2e3 days
pv, although signiﬁcant up-regulation of IFN-g was also evident
after 5 days (also named IFN-II), as also observed at different times
for Mx-1, IL8 and IL12 in the vaccinated ﬁsh with respect to the ﬁsh
fed with the empty plasmid. In turn, ﬁsh IFN II can induce the
expression of many interferon induced genes (ISGs) that also
respond to type I IFNs, suggesting cross-activation of the innate
antiviral responses elicited by type I and II IFNs. Our results showed
that the VP2 vaccine also modulates pro-inﬂammatory cytokines
like IL-12, which was signiﬁcantly up-regulated at 2, and even 7
days pv. Moreover, interleukin 8 (IL-8) was also rapidly up-
regulated, a gene included in the CXCa group of chemokines, a
family of cytokines that regulate immune cell migration under both
inﬂammatory and normal physiological conditions. These genes
not only promote leukocyte mobilization but also, they regulate the
immune responses and differentiation of the recruited cells.
Accordingly, they have been catalogued as key regulators of the
immune response, acting as a bridge between the innate and
adaptive responses [47]. Strong IL8 expression has been also re-
ported following IHNV and VHSV infection, suggesting a role for
this cytokine in viral defence [48,49].
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adaptive immune response, immunoglobulins (Ig) M and T, and the
Th cell markers CD4 and CD8. In mammals, Igs can be divided into
ﬁve categories and for a long time, it was believed that only one of
them, IgM, existed in ﬁsh. However several other functional Igs have
recently been discovered in teleost ﬁsh and Ig genes were identiﬁed
in rainbow trout, named IgT, similar to zebra ﬁsh IgZ [50]. It was also
recently reported that rainbow trout contained a new B linage
uniquely expressing surface IgT [44]. It is interesting that genes
related to adaptive immunity were already being expressed by the
7thdayafter the last feedwith the vaccine (the10thdayafter theﬁrst
feed), which could be relevant for the effectiveness of the vaccine.
We recently studied immune responses in the rainbow trout gut
and pyloric caeca region, the area inwhich a major recruitment of B
cells was demonstrated [51]. Moreover, we found signiﬁcant in-
creases in the number of both IgMþ and IgTþ intraepithelial lym-
phocytes after manual oral vaccination with the pcDNA-VP2
vaccine. In the present work, the head kidney was the target organ
assayed, considered to be the primary lymphoid tissue in teleost
ﬁsh and thus, an important source of B cells. The IgM and IgT genes
were evaluated here at 15 and 30 days pv when the adaptive im-
mune responses may be more apparent. Interestingly, the expres-
sion of both these genes peaked 30 days pv, suggesting the
presence of Ig secreting cells, and corroborating the vaccine activity
and the gene response to oral stimulation.
The level of expression was also evaluated for other genes, such
as CD4 and CD8, although the transcription of these Tcell genes was
not signiﬁcantly enhanced. This might be explained by differences
between ﬁshes and their ingestion ability, as well as the times
selected for the assay. IFN-g is mainly produced by CD4þ cells in
mammals and this gene was signiﬁcantly up-regulated at 7 days pv,
suggesting an activation induced by the vaccine. Further sampling
of other organs and assessing the time-course of expression will be
necessary to study the mechanisms and pathways that an oral
vaccine could initiate in more depth. Here, we only aimed to assay
the viability of the feed-delivery method to induce a variety of
immune responses. Nevertheless, we demonstrated that VP2 is
expressed in organs and that it orchestrates immune responses.
A detailed comparison with the results we obtained previously
with an oral vaccine cannot be carried out, since the vaccinee
alginate complexes were administered individually on only one
dose [34,35] while here the ﬁsh were fed with the vaccine over 3
consecutive days. Nevertheless, similar proﬁles of expression were
observed over the ﬁrst 3e7 days using both methods of oral
administration, although the response was stronger when the
vaccine was administered in the feed. Peaks of expression were
recorded around the 7th day post-vaccination with a pipette, and
on the 3rd day (more-or-less) in the present study, which is 6 days
after the ﬁsh received their ﬁrst feed with the vaccine.With regards
IgM and IgT expression, data were only recorded after the ﬁrst 8
days post-vaccination in the previous study, when there was only
weak induction of these genes (3-fold). Here these antibody re-
sponses were examined at 15 and 30 days post-vaccination,
considered as markers of adaptive immune response, when
values around 15-fold were recorded.With regards protection, both
methods to deliver the pcDNA.VP2 vaccine diminished the mor-
tality from the very ﬁrst days post-challenge, which may be related
to the innate-immune response induced. Moreover, strong speciﬁc
protectionwas evident 30 days post-challenge, as demonstrated by
the levels of the neutralizing antibodies recorded and by the cu-
mulative mortality. Taken together, these data show that the
pcDNA.VP2 vaccine administered with the feed is stable in the
gastric system of the ﬁsh, allowing efﬁcient absorption of the an-
tigen, as well as the subsequent induction of innate and adaptive
responses.To fully assess the effectiveness of the vaccine and delivery
method, vaccinated and control ﬁsh were challenged with virulent
IPNV at 15 and 30 day pv, and cumulative mortality was examined
over 30 days. The vaccinated trout displayed strong protection,
similar levels to those previously described for ﬁsh that were
individually vaccinated with alginate-encapsulated plasmid [29].
The cumulative mortality was similar in the replicate experiments
performed, despite the possible variability in feed uptake over the 3
days of vaccination. Interestingly, very low levels of mortality were
recorded during the ﬁrst 10e12 days in all the vaccinated ﬁsh,
suggesting an antiviral effect induced by the activation of IFN and
other genes involved in immune responses. Mild protection was
also initially evident in the pcDNA vaccinated ﬁsh, although their
ﬁnal mortality was the same as in the virus control group. In the
vaccinated ﬁsh the early protective effect seems to be followed by a
later phase of speciﬁc immunity, as the vaccine induced the pro-
duction of neutralizing antibodies against IPNV. Since the survival
rates recorded are higher when ﬁsh were challenged on the 15th
day pv, an overlap of both the innate and adaptive protective effects
might occur at this time. Despite the role of non-speciﬁc defence
mechanisms, it is noteworthy how effective the oral DNA vaccine
and the VP2 antigen are in progressively inducing the appearance
of neutralizing antibodies, and hence, speciﬁc protection.
Viral load was quantiﬁed by RT-qPCR at 45 days post-challenge
in vaccinated virus challenged ﬁsh and in virus control trout. Fish
from both groups were survivors that displayed no clinical symp-
toms of disease, yet the expression of the IPNV-VP4 gene detected
in the infected non-vaccinated ﬁsh was signiﬁcantly higher than
that recorded in those that received the vaccine, suggesting that
vaccination reduced viral load. However, PCR detection of a viral
gene does not necessarily imply the presence of infective virions, as
demonstrated by failure to recover IPNV after inoculation of cell
cultures with homogenates from the head kidney from ﬁsh (data
not shown). Experiments over longer periods than those carried
out here would be necessary to determine whether PCR could
detect the virus after several months. Meanwhile our results indi-
cate that in the present conditions, the oral vaccine clearly dimin-
ished the viral load in the ﬁsh. Thus, these results demonstrated
that administration through feeding is a promising delivery
method, at least for IPNV vaccines.
Few studies on DNA oral vaccines against this or other ﬁsh vi-
ruses have been performed to date. Some preliminary experiments
with an oral vaccine against IHNV did not prove to be as efﬁcient
(unpublished data) and a recent study on oral administration of a
DNA anti-IHNV vaccine described inefﬁcient protection, although
the viability of oral delivery of DNA vaccines was demonstrated
[52].
Protection is likely to increase as the doses, encapsulating ma-
terials and methods to add the vaccine to the feed improves. The
effective uptake of the DNA vaccine and its transcription by enter-
ocytes along the ﬁve segments of the digestive tract was suggested
in our recent study in which the vaccine was delivered manually as
microspheres suspended in solution [51]. The pyloric caeca was the
area of the digestive tract in which a major recruitment of B cells
was detected and the most responsive to the oral IPNV vaccination
of the ﬁve segments examined. In this work, the increase in VP2
mRNA transcripts at 3 days rose further to peak in the gut after 5
days of vaccination. The second segment of the gut (as described by
Rombout et al. [53]) is considered the regionwhere a strong uptake
of macromolecules takes place after the ﬁsh were fed for 3 days.
However, while VP2 expression peaked in the kidney at 15 days pv,
only basal levels of expressionwere recorded in the gut at that time
of vaccination, suggesting that plasmid DNAwas then redistributed
to other tissues and only small amounts of VP2 expression persisted
at this site.
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kidney, peaking at 5 and 15 days pv, respectively, and producing
stronger expression in the intestine. This is interesting because our
knowledge of mucosal immunity is progressing and the recent
discoveries regarding gut immunoglobulin open up new opportu-
nities for the study of oral vaccines. It is believed that the teleost
ﬁsh intestine does not contain organized lymphoid tissue but
rather, the equivalent of M-cells that can capture, transport and
present antigens to the underlying mucosal immune system
[53,54]. The distal intestine of salmonids is well known to have
strong vesicular transport activity compared to the proximal in-
testine [55]. The passage of an oral DNAvaccine through the gastro-
intestinal tract may be crucial because it is believed that intact
antigen must reach the distal part of the gut to ensure uptake and
transport by the epithelial cells. The strong responsiveness of the
gut needs to be paid more attention as there is evidence that the
gastrointestinal tract is an entry route for IPNV in Atlantic salmon
[54], and that the virus can modulate the barrier function and
transport activities of the intestinal epithelium.
The need for new insights into ﬁsh vaccination is evidence of the
advance in our understanding of innate and adaptive immune re-
sponses. A recent review on IPNV vaccines [56] clearly shows that
antigen delivery systems and routes of vaccine delivery inﬂuence
the type of adaptive immune response generated in the host. Oral
vaccines against IPNV and other viruses should be explored not
only for their systemic immunity but also for the mucosal immu-
nity they can induce. Determining the relevance of the gut as an
immune-competent organwill be a promising area of study. Finally,
our results indicate that as well as injection, incorporating the
vaccine into food pellets seems to be a promising oral delivery
method for the vaccination of cultured ﬁsh.Acknowledgements
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